Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Hims & Hers Health, Inc. (HIMS) closed the latest trading day at $27.23, indicating a +1.57% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of ...

For fitness enthusiasts who need a little cardio variety, HIIT (or high-intensity interval training) has long been a popular choice. According to a study in Biology of Sport, HIIT — which pairs short ...